Share This Article:
Establishing a causal relationship in Long COVID may be established by a potential blood bio-marker according to a recently published study.
"The diagnosis and management of post-acute sequelae of COVID-19 (PASC) poses an ongoing medical challenge. Identifying biomarkers associated with PASC would immensely improve the classification of PASC patients and provide the means to evaluate treatment strategies. We analyzed plasma samples collected from a cohort of PASC and COVID-19 patients (n = 63) to quantify circulating viral antigens and inflammatory markers. Strikingly, we detect SARS-CoV-2 spike antigen in a majority of PASC patients up to 12 months post-diagnosis, suggesting the presence of an active persistent SARS- CoV-2 viral reservoir. Furthermore, temporal antigen profiles for many patients show the presence of spike at multiple time points over several months, highlighting the potential utility of the SARS-CoV-2 full spike protein as a biomarker for PASC.
"While symptoms resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically resolve within a few weeks, some individuals experience persistent symptoms following the acute phase of coronavirus disease (COVID-19). The associated syndrome, termed post-acute sequelae of COVID-19 (PASC) or long COVID, encompasses a range of symptoms, including, but not limited to, fatigue, anosmia, memory loss, gastrointestinal distress, and shortness of breath. Estimates vary as to the prevalence of PASC, but the World Health Organization (WHO) reports around one quarter of individuals with COVID-19 continue to experience symptoms 4-5 weeks after a positive test and approximately one in 10 have continuing symptoms after 12 weeks.
Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae, medRxiv preprint doi: https://doi.org/10.1101/2022.06.14.22276401; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license.
By Jon L. Gelman
Courtesy of Workers' Compensation
Read Also
- Aug 12, 2024
- Frank Ferreri
- Aug 06, 2024
- Frank Ferreri
About The Author
About The Author
- WorkersCompensation.com
More by This Author
- Jun 24, 2024
- WorkersCompensation.com
- May 11, 2023
- WorkersCompensation.com
- May 10, 2023
- WorkersCompensation.com
Read More
- Aug 12, 2024
- Frank Ferreri
- Aug 06, 2024
- Frank Ferreri
- Aug 05, 2024
- Frank Ferreri
- Aug 02, 2024
- Frank Ferreri
- Jul 01, 2024
- Frank Ferreri